Bacillus Calmette-Guérin (BCG) vaccine
GPTKB entity
Statements (53)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:vaccine
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Camille_Guérin
|
gptkbp:appointed_by |
intradermal injection
|
gptkbp:average_temperature |
2 to 8 degrees Celsius
|
gptkbp:category |
live attenuated vaccine
tuberculosis vaccine oncological vaccine |
gptkbp:clinical_trial |
Phase III
|
gptkbp:contraindication |
pregnancy
immunocompromised individuals |
gptkbp:defense |
included in the EPI (Expanded Programme on Immunization)
|
gptkbp:developed_by |
gptkb:Camille_Guérin
gptkb:Albert_Calmette |
gptkbp:first_introduced |
gptkb:1921
|
https://www.w3.org/2000/01/rdf-schema#label |
Bacillus Calmette-Guérin (BCG) vaccine
|
gptkbp:is_effective_against |
reduces severe forms of tuberculosis
variable efficacy against pulmonary tuberculosis |
gptkbp:is_used_for |
bladder cancer treatment
tuberculosis prevention |
gptkbp:is_vulnerable_to |
single dose
preventive vaccine lower in adults therapeutic vaccine may reduce risk of certain cancers provides some protection against non-tuberculous mycobacterial infections provides some protection against childhood infections high in children may enhance immune response to other vaccines may reduce risk of Crohn's disease may reduce risk of allergic diseases may reduce risk of asthma may reduce risk of multiple sclerosis may reduce risk of type 1 diabetes may reduce risk of ulcerative colitis multiple doses in some cases provides some protection against leprosy reduces incidence of TB reduces morbidity from TB reduces mortality from TB provides some protection against respiratory infections |
gptkbp:manager |
intradermal
|
gptkbp:marketed_as |
various brand names
|
gptkbp:produced_by |
gptkb:Mycobacterium_bovis
|
gptkbp:side_effect |
fever
swelling at injection site abscess formation disseminated BCG infection local skin reaction lymphadenitis osteitis |
gptkbp:suitable_for |
infants in high TB prevalence areas
|
gptkbp:type |
live attenuated vaccine
|